Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Akari Therapeutics, Plc is a biotechnology company focused on developing innovative therapies for rare diseases, particularly through its lead product candidate, nomacopan, which targets complement-mediated diseases. The company operates primarily in the United States and Europe, leveraging a unique mechanism of action that differentiates its therapies from conventional treatments.
Akari Therapeutics aims to generate revenue through the commercialization of its lead product candidate, nomacopan, which is designed to treat conditions such as dry eye disease and other complement-mediated disorders. The company has a competitive advantage due to its proprietary technology platform that allows for targeted therapies, potentially leading to better patient outcomes and reduced side effects compared to existing treatments.
Clinical trial results for nomacopan, particularly Phase 3 outcomes
Regulatory approvals from the FDA or EMA for nomacopan
Partnership announcements for commercialization or development
Market adoption rates of nomacopan upon launch
Regulatory changes that could impact drug approval processes
Technological disruption in biotechnology that could render current approaches obsolete
Emergence of alternative therapies targeting similar diseases
Established competitors with more resources and market presence
High cash burn rate leading to potential liquidity issues
Dependence on external funding for ongoing clinical trials
low - The demand for biotechnology products is less sensitive to economic cycles, as they often address critical health needs regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for R&D funding, potentially impacting the company's ability to finance its clinical trials.
minimal - The company has low debt levels, which reduces its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has exhibited significant price volatility, particularly in response to clinical trial news.